Detailed price information for Crescent Biopharma Inc (CBIO-Q) from The Globe and Mail including charting and trades.

While anti-VEGF therapy is the standard for DME and nAMD, managing nonresponders with persistent fluid remains a clinical ...

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multip ...

Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships ...

A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...

Hutchmed, Innovent receive NMPA nod for fruquintinib in combo with sintilimab injection to treat patients with metastatic renal cell carcinoma: Hong Kong, Shanghai Saturday, May 2 ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the ...

Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with ...

Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.

The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, ...